Advertisement

Topics

Active-Investors: Blog Exposure - FDA Grants Orphan Drug Designation to Avadel Pharma's FT 218 For Treatment Of Narcolepsy

07:45 EST 12 Jan 2018 | FinanzNachrichten

LONDON, UK / ACCESSWIRE / January 12, 2018 / Active-Investors.com has just released a free research report on Avadel Pharma PLC (NASDAQ: AVDL). If you want access to this report all you need to do ...

Original Article: Active-Investors: Blog Exposure - FDA Grants Orphan Drug Designation to Avadel Pharma's FT 218 For Treatment Of Narcolepsy

NEXT ARTICLE

More From BioPortfolio on "Active-Investors: Blog Exposure - FDA Grants Orphan Drug Designation to Avadel Pharma's FT 218 For Treatment Of Narcolepsy"

Advertisement
Quick Search
Advertisement
Advertisement